Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Rohto Pharmaceutical Co ( (JP:4527) ) has provided an update.
Rohto Pharmaceutical has adjusted the conversion price of its ¥25 billion zero coupon convertible bonds due 2032, lowering it from ¥2,828.5 to ¥2,817.2 per share. The revised conversion price applies retroactively from the day after the 31 March 2026 record date, aligning the bond terms with the company’s latest shareholder return policy.
The change in conversion price was triggered by the approval and payment of an annual dividend of ¥46 per share, as decided by the board on 21 May 2026. This adjustment reflects standard anti-dilution mechanisms and indicates Rohto’s continued commitment to dividends while maintaining fair conditions for bondholders and equity investors.
The most recent analyst rating on (JP:4527) stock is a Buy with a Yen2980.00 price target. To see the full list of analyst forecasts on Rohto Pharmaceutical Co stock, see the JP:4527 Stock Forecast page.
More about Rohto Pharmaceutical Co
Rohto Pharmaceutical Co., Ltd., listed on the TSE Prime market, operates in the pharmaceutical industry with a focus on healthcare and related products. The company serves both domestic and international markets and is led by President and Representative Director Hidetoshi Segi, with financial oversight by Vice President and CFO Masaya Saito.
Average Trading Volume: 822,721
Technical Sentiment Signal: Buy
Current Market Cap: Yen591B
See more data about 4527 stock on TipRanks’ Stock Analysis page.